Experience with B-cell lymphoma at a South African centre in the HIV Era

Transfusion and Apheresis Science

Volumn 49, Issue 1, 2013, Pages 31-39

  Davidson, Alan ^a   Hendricks, Marc ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EFAVIRENZ; ETOPOSIDE; IFOSFAMIDE; LAMIVUDINE; METHOTREXATE; PREDNISONE; RITUXIMAB; STAVUDINE; VINCRISTINE; ZIDOVUDINE;

ADOLESCENT; AFRICA; ARTICLE; B CELL LYMPHOMA; B LYMPHOBLAST; BACTERIUM CULTURE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CONTROLLED STUDY; DEATH; DISEASE COURSE; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FUNGUS CULTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LARGE CELL LYMPHOMA; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; THROMBOCYTE TRANSFUSION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; LYMPHOMA, AIDS-RELATED; LYMPHOMA, B-CELL; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; SOUTH AFRICA;

EID: 84882885753     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2013.05.022     Document Type: Article

References (39)

1. Cairo M.S., Gerrard M., Sposto R., Auperin A., Pinkerton C.R., Michon J., et al. On behalf of the FAB LMB96 International study committee. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007, 109:2736-2743.
2. Patte C., Auperin A., Gerrard M., Michon J., Pinkerton R., Sposto R., et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007, 109:2773-2780.
3. Davidson A., Desai F., Hendricks M., Hartley P., Millar A., Numanoglu A., et al. The evolving management of Burkitt's lymphoma at Red Cross Children's Hospital. S Afr Med J 2006, 96:950-954.
4. Chiappini E., Galli L., Tovo P.-A., Gabiano C., Lisi C., Giaquinto C., et al. Cancer rates after year 2000 significantly decrease in children with perinatal HIV infection: a study by the Italian register for HIV infection in children. J Clin Oncol 2007, 25:97-101.
5. Stack M., Walsh P.M., Comber H., Ryan C.A., O'Lorcain P. Childhood cancer in Ireland: a population-based study. Arch Dis Child 2007, 92:890-897.
6. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. (editors). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, based on November 2006 SEER data submission, posted to the SEER web site; 2007 [accessed 27.09.12]. http://www.seer.cancer.gov/csr/1975_2004/.
7. Centers for Disease Control and Prevention US HIV and AIDS cases reported through December 1996. HIV/AIDS Surveill Rep 1996, 8:1-39.
8. Biggar R.J., Frisch M., Goedert J.J. Risk of cancer in children with AIDS. JAMA 2000, 284:205-209.
9. Granovsky M.O., Mueller B.U., Nicholson H.S., Rosenberg P.S., Rabkin C.S. Cancer in human immunodeficiency virus-infected children: a case series from the Children's Cancer Group and the National Cancer Institute. J Clin Oncol 1998, 16:1729-1735.
10. Caselli D., Klersy C., de Martino M., Gabiano C., Galli L., Tovo P.A., et al. Human immunodeficiency virus-related cancer in children: Incidence and treatment outcome - report of the Italian register. J Clin Oncol 2000, 18:3854-3861.
11. Davidson A., Hendricks M., Geel J., Wainwright L., Stones D. Malignancy in HIV-positive South African Children. Pediatr Blood Cancer 2009, 53:719. [Abstract].
12. Davidson A. Treatment options for HIV-positive children with B-cell lymphomas. Pediatr Blood Cancer 2010, 55:778. [Abstract].
13. Griffin T.C., Weitzman S., Weinstein H., Chang M., Cairo M., Hutchison R., et al. Children's Oncology Group. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009, 52:177-181.
14. Meinhardt A., Burkhardt B., Zimmermann M., Borkhardt A., Kontny U., Klingebiel T., et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 2010, 28:3115-3121.
15. Cairo M.S., Lynch J.C., Harrison L., Perkins S.L., Shiramizu B., Gross T., et al. Safety, pharmacokinetics (PK) and outcome following Rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with Stage III/IV (Group B) and BM+/CNS+ (Group C) mature B-NHL: a Children's Oncology Group Report. J Clin Oncol 2010, 28:S9536. [Abstract].
16. Patte C., Auperin A., Michon J., Behrendt H., Leverger G., Frappaz D., et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001, 97:3370-3379.
17. Anderson J.R., Jenkin R.D., Wilson J.F., Kjeldsberg C.R., Sposto R., Chilcote R.R., et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Children's Cancer Group. J Clin Oncol 1993, 11:1024-1032.
18. Wrobel G., Mauguen A., Rosolen A., Reiter A., Williams D., Horibe K., et al. European Inter-Group for Childhood, Non-Hodgkin Lymphoma (EICNHL). Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial. Pediatr Blood Cancer 2011, 56:1071-1077.
19. Garcia J.F., Mollejo M., Fraga M., Forteza J., Muniesa J.A., Perez-Guillermo M., et al. Large B-cell lymphoma with Hodgkin's features. Histopathology 2005, 47:101-110.
20. Traverse-Glehen A., Pittaluga S., Gaulard P., Sorbara L., Alonso M.A., Raffeld M., et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Path 2005, 29:1411-1421.
21. Miles R.R., Arnold S., Cairo M.S. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br J Haem 2012, 156:730-743.
22. Sinfield R.L., Molyneux E.M., Banda K., Borgstein E., Broadhead R., Hesseling P., et al. Spectrum and presentation of pediatric malignancies in the HIV era: experience from Blantyre, Malawi, 1998-2003. Pediatr Blood Cancer 2007, 48:515-520.
23. Evans J.A., Gibb D.M., Holland F.J., Tookey P.A., Pritchard J., Ades A.E. Malignancies in UK children with HIV infection acquired from mother to child transmission. Arch Dis Child 1997, 76:330-333.
24. Besson C., Goubar A., Gabarre J., Willy Rozenbaum W., Pialoux G., Châtelet F.P., et al. Changes in AIDS-related lymphoma since the era of highly active anti-retroviral therapy. Blood 2001, 98(8):2339-2344.
25. Radhakrishnan R., Suhas S., Kumar R.V., Krishnanand G., Srinivasan R., Rao N.N. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005, 100:725-731.
26. Mueller B., Pizzo P.A. Malignancies in pediatric AIDS. Curr Opin Pediatr 1998, 8:45-49.
27. Saple D.G., Shah I., Surjushe A.U., Murthy A., Chudgar P., Gote P.D. Lymphoma in HIV patients: varied presentations. Ind J Med Pediatr Oncol 2010, 31:39-42.
28. Bower M., McCall-Peat N., Ryan N., Davies L., Young A.M., Gupta S., et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004, 104:2943-2946.
29. Ratner L., Lee J., Tang S., Redden D., Hamzeh F., Herndier B., et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active anti-retroviral therapy. J Clin Oncol 2001, 19:2171-2178.
30. Vaccher E., Spina M., di Gennaro G., Talamini R., Nasti G., Schioppa O., et al. Concomitant cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy plus highly active anti-retroviral in patients with immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001, 91:155-163.
31. Little R.F., Pittaluga S., Grant N., Steinberg S.M., Kavlick M.F., Mitsuya H., et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose adjusted EPOCH: impact of antiretroviral therapy suspension and tumour biology. Blood 2003, 101:4653-4659.
32. Vishnu P, Aboulafia DM. AIDS-related Non-Hodgkin's Lymphoma in the Era of Highly active Antiretroviral Therapy. Adv Hematol 2012: Epub 6 Feb.
33. Attias D., Weitzman S. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukaemia: a review of available evidence. Curr Opin Pediatr 2008, 20:17-22.
34. Habermann T.M., Weller E.A., Morrison V.A., Gascoyne R.D., Cassileth P.A., Cohn J.B., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121-3127.
35. Pfreundschuh M., Trümper L., Osterborg A., Pettengell R., Trneny M., Imrie K., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diff use large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391.
36. Ladenstein R., Pearce R., Hartmann O., Patte C., Goldstone T., Philip T. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 1997, 90:2921-2930.
37. Attarbaschi A., Dworzak M., Steiner M., Urban C., Fink F.M., Reiter A., et al. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer 2005, 44:70-76.
38. Harris R.E., Termuhlen A.M., Smith L.M., Lynch J., Henry M.M., Perkins S.L., et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. Biol Blood Marrow Transpl 2011, 17:249-258.
39. Gross T.G., Hale G.A., He W., Camitta B.M., Sanders J.E., Cairo M.S., et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transpl 2010, 16:223-230.